Is the fat redistributed after complete release of the tear‑trough (orbicularis‑retaining) ligament placed in the supraperiosteal or subperiosteal plane, and how can damage to the infraorbital nerve be avoided?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 28, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Plane of Fat Redistribution and Infraorbital Nerve Protection in Tear Trough Surgery

Plane of Fat Redistribution

After complete release of the tear trough (orbicularis-retaining) ligament, fat is redistributed in the supraperiosteal plane, positioned above the periosteum but below the orbicularis oculi muscle. 1, 2

Technical Details of Fat Placement

  • The supraperiosteal pocket is created below the orbicularis oculi muscle using blunt scissor dissection after the arcus marginalis is released. 1

  • Fat pedicles are transposed and anchored across the orbital rim with 5-0 polyglactin sutures, securing both the orbital fat and orbital septum in the supraperiosteal space. 1

  • An alternative technique places fat above the orbicularis muscle (rather than below it in the supraperiosteal plane), which has shown comparable long-term results with no major complications and may simplify the dissection. 2

Anatomical Rationale

  • The orbicularis retaining ligament consists of two layers: the upper layer originates from the orbital margin medially and from preorbital walls laterally, while the lower layer originates from preorbital walls and passes through the orbicularis muscle and superficial fat before ending at the skin. 3

  • Complete release of this ligament eliminates the tethering effect that creates the tear trough deformity, allowing fat redistribution to fill the hollow concavity. 4

  • The tear trough measures approximately 16.56 mm in length, with width varying from 2.06 mm at the inner canthus to 3.25 mm at the lateral alar margin. 3

Protection of the Infraorbital Nerve

The infraorbital nerve is protected by maintaining dissection in the supraperiosteal plane and avoiding deep penetration beyond the orbital rim during pocket creation.

Specific Technical Safeguards

  • Limit dissection depth: The supraperiosteal pocket should be created with blunt scissor dissection, staying superficial to the periosteum where the infraorbital nerve exits its foramen approximately 6-8 mm below the orbital rim. 1

  • Controlled arcus marginalis release: Release the arcus marginalis using cautery cutting rather than sharp dissection to maintain precise control and avoid deep penetration that could injure the nerve. 1

  • Avoid lateral extension: The dissection should not extend excessively lateral or inferior to the planned fat repositioning area, as the infraorbital nerve courses obliquely across the maxilla after exiting its foramen. 1

  • Use preseptal approach: Performing preseptal dissection (rather than postseptal) and extending over the arcus marginalis provides a safer plane that keeps the surgeon away from deeper neurovascular structures. 1

Clinical Outcomes and Safety Profile

  • In a prospective study of 20 young Asian patients, no major complications including nerve injury, lower eyelid retraction, ectropion, or diplopia were observed using the supraperiosteal technique. 1

  • A larger series of 105 patients with mean 31-month follow-up showed effective tear trough correction with no compromise of tarsoligamentous support and no ectropion development in any patient. 4

  • The supramuscular fat placement technique (above rather than below the orbicularis) demonstrated no contour irregularities or significant long-term complications in 41 patients followed for minimum 44 months. 2

Common Pitfall to Avoid

The critical error is creating the pocket too deep (subperiosteal rather than supraperiosteal) or extending dissection too far inferiorly, which places the infraorbital nerve at direct risk of injury from instruments or suture placement. 1 Maintaining blunt dissection in the correct anatomical plane and limiting the extent of pocket creation to the immediate suborbital region minimizes this risk.

Related Questions

In an adult undergoing lower‑eyelid or mid‑face rejuvenation, after incising the periosteum at the orbital rim to release the arcus marginalis, how can the dissection be continued inferiorly in the supraperiosteal plane rather than the subperiosteal plane?
In lower eyelid fat transposition, is subperiosteal placement of the fat permissible, what is the safe inferior dissection limit, and how can injury to the infraorbital nerve be prevented?
What is the incidence of fat entrapment after lower‑lid blepharoplasty with fat transposition, and how can it be completely prevented?
How can I ensure complete release of the tear‑trough (orbicularis‑retaining) ligament during lower‑lid blepharoplasty?
In lower‑lid blepharoplasty for typical adult cosmetic patients without significant ocular disease, lid laxity, or wound‑healing comorbidities, is it safe to perform only fat transposition and reserve fat excision only for cases with truly bulky or protruding orbital fat?
How should I evaluate and treat cadmium toxicity in a middle‑aged adult with possible occupational exposure presenting with proteinuria, reduced renal function, bone pain, and respiratory symptoms?
What is the first-line therapy for Clostridioides difficile infection in adults and how should recurrences be managed?
What is the recommended evaluation and management for an incidental empty sella turcica, including endocrine screening and treatment of possible intracranial hypertension?
What is the appropriate evaluation and management of hypokalemia in a patient with chronic lung disease (e.g., COPD, asthma, interstitial lung disease, or bronchiectasis)?
I've had a cough for 2 months, hoarseness for 1 month, and now small amounts of blood when I cough; a short course of cephalexin, promethazine, and prednisone a month ago only helped briefly before symptoms returned. What should I do?
What is the appropriate initial evaluation and management for a patient with fatigue and a white blood cell count of 27 × 10^9/L?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.